85 related articles for article (PubMed ID: 28730642)
1. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.
Aukema SM; van Pel R; Nagel I; Bens S; Siebert R; Rosati S; van den Berg E; Bosga-Bouwer AG; Kibbelaar RE; Hoogendoorn M; van Imhoff GW; Kluin-Nelemans HC; Kluin PM; Nijland M
Histopathology; 2017 Dec; 71(6):960-971. PubMed ID: 28730642
[TBL] [Abstract][Full Text] [Related]
2. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract][Full Text] [Related]
3. Oral follicular lymphoma: a clinicopathologic and molecular study.
Souza LL; Cáceres CVBL; Sant'Ana MSP; Penafort PVM; Andrade BAB; Pontes HAR; Castro WH; Mesquita RA; Xavier-Júnior JCC; Santos-Silva AR; Lopes MA; Soares CD; Robinson L; van Heerden WFP; Burbano RMR; Assis-Mendonça GR; Vassallo J; Sousa SF; Vargas PA; Fonseca FP
J Hematop; 2023 Dec; 16(4):199-208. PubMed ID: 38175434
[TBL] [Abstract][Full Text] [Related]
4.
Minagawa K; Wakahashi K; Fukui C; Kawano Y; Kawano H; Suzuki T; Ishii S; Sada A; Nishikawa S; Asada N; Katayama Y; Matsui T
Front Immunol; 2023; 14():1197112. PubMed ID: 37304286
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
[TBL] [Abstract][Full Text] [Related]
6. Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?
Katsushima H; Fukuhara N; Konosu-Fukaya S; Himuro M; Kitawaki Y; Ichikawa S; Ishizawa K; Sasano H; Harigae H; Ichinohasama R
Leuk Lymphoma; 2018 Mar; 59(3):758-762. PubMed ID: 28771060
[No Abstract] [Full Text] [Related]
7. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
Yao Z; Deng L; Xu-Monette ZY; Manyam GC; Jain P; Tzankov A; Visco C; Bhagat G; Wang J; Dybkaer K; Tam W; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Møller MB; Winter JN; Piris MA; Fayad L; Liu Y; Song Y; Orlowski RZ; Kantarjian H; Medeiros LJ; Li Y; Cortes J; Young KH
Leukemia; 2018 Feb; 32(2):353-363. PubMed ID: 28745330
[TBL] [Abstract][Full Text] [Related]
8. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
Quesada AE; Medeiros LJ; Desai PA; Lin P; Westin JR; Hawsawi HM; Wei P; Tang G; Seegmiller AC; Reddy NM; Yin CC; Wang W; Xu J; Miranda RN; Zuo Z; Li S
Mod Pathol; 2017 Dec; 30(12):1688-1697. PubMed ID: 28776574
[TBL] [Abstract][Full Text] [Related]
9. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
Ott G
Br J Haematol; 2017 Sep; 178(6):871-887. PubMed ID: 28748558
[TBL] [Abstract][Full Text] [Related]
10. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
12. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.
Bouska A; Bi C; Lone W; Zhang W; Kedwaii A; Heavican T; Lachel CM; Yu J; Ferro R; Eldorghamy N; Greiner TC; Vose J; Weisenburger DD; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; Siebert R; Miles RR; Dave S; Reddy A; Delabie J; Staudt LM; Song JY; McKeithan TW; Fu K; Green M; Chan WC; Iqbal J
Blood; 2017 Oct; 130(16):1819-1831. PubMed ID: 28801451
[TBL] [Abstract][Full Text] [Related]
13. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
[TBL] [Abstract][Full Text] [Related]
14. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
Weigert O; Weinstock DM
Blood; 2017 Sep; 130(13):1491-1498. PubMed ID: 28784599
[TBL] [Abstract][Full Text] [Related]
15. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.
Zamò A; Pischimarov J; Schlesner M; Rosenstiel P; Bomben R; Horn H; Grieb T; Nedeva T; López C; Haake A; Richter J; Trümper L; Lawerenz C; Klapper W; Möller P; Hummel M; Lenze D; Szczepanowski M; Flossbach L; Schreder M; Gattei V; Ott G; Siebert R; Rosenwald A; Leich E
Leukemia; 2018 Mar; 32(3):685-693. PubMed ID: 28824170
[TBL] [Abstract][Full Text] [Related]
16. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266
[TBL] [Abstract][Full Text] [Related]
18. Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
Paul U; Richter J; Stuhlmann-Laiesz C; Kreuz M; Nagel I; Horn H; Staiger AM; Aukema SM; Hummel M; Ott G; Spang R; Rosenwald A; Feller AC; Cogliatti S; Stein H; Hansmann ML; Moller P; Szczepanowski M; Burkhardt B; Pfreundschuh M; Schmitz N; Loeffler M; Trümper L; Siebert R; Klapper W
Leuk Lymphoma; 2018 May; 59(5):1213-1221. PubMed ID: 28838257
[TBL] [Abstract][Full Text] [Related]
19.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
20. Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
Klymenko T; Bloehdorn J; Bahlo J; Robrecht S; Akylzhanova G; Cox K; Estenfelder S; Wang J; Edelmann J; Strefford JC; Wojdacz TK; Fischer K; Hallek M; Stilgenbauer S; Cragg M; Gribben J; Braun A
Leukemia; 2018 Feb; 32(2):364-375. PubMed ID: 28804121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
